Plasmid News and Research

RSS

A nanoscaffolding approach for rapid design of highly immunogenic SARS-CoV-2 vaccines

A research group from Slovenia, Switzerland, and Germany shows how nanoscaffolded assemblies may neutralize interaction between the SARS-CoV-2 spike protein and cell receptor, providing adequate protection in a surrogate infection assay and warranting the advance of such platforms in the pursuit for the effective vaccine.

31 Aug 2020

Heat Biologics SARS-CoV-2 vaccine generates potent T cell response in pre-clinical trial

The COVID-19 pandemic is still creating economic and health-related impact over the world. A new study published on the preprint server bioRxiv in August 2020 shows that a gp96-Ig-secreting vaccine candidate based on the expression of full-length spike protein generates a potent T cell response.

26 Aug 2020

Discovery offers new hope for millions at risk from antibiotic-resistant infections

There is new hope for approximately 700,000 people who die each year from antibiotic resistant infections, with University of Queensland researchers discovering how bacteria share antibiotic-resistance genes.

17 Aug 2020

Influenza-virus-based vaccine platform another viable option against SARS-CoV-2

In a novel proof of concept study, published on the bioRxiv preprint server, U.S. researchers used attenuated influenza viral particles that express severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) receptor-binding domain to induce neutralizing antibodies in mice – unveiling another viable vaccine candidate for preventing coronavirus disease (COVID-19).

14 Aug 2020

Synthetic riboregulators detect SARS-CoV-2 genome parts in 40 minutes

By exploiting the tools of synthetic biology, the researchers from Turkey have successfully developed a de novo riboregulator system for rapidly detecting the presence of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) genomic material. Their paper is currently available on medRxiv preprint server.

2 Aug 2020

Touchlight, Cancer Research UK and University of Southampton team up to develop DNA cancer vaccine

Cancer Research UK, the University of Southampton and Touchlight Genetics, a London based biotechnology company, today (Wednesday) announce a new clinical development partnership to progress a therapeutic DNA vaccine, TGL-100, into an early phase clinical trial targeting head and neck squamous cell carcinoma.

31 Jul 2020

Game-Changer: A SARS-CoV-2 serological test for 50-cents per sample!

A recent study published in the preprint server medRxiv in July 2020 shows that this is indeed possible. The development of this inexpensive but reliable and sensitive test could change the face of preventive measures for COVID-19 in low-resource settings.

17 Jul 2020

Novel antibody test for SARS-CoV-2

A team of researchers in the United States have developed highly specific and sensitive assays that could improve understanding of the antibody response in coronavirus disease 2019 (COVID-19) and help to determine the effectiveness of vaccines.

9 Jul 2020

Researchers perform first X-ray measurements on SARS-CoV-2 main protease

A team of researchers at the Department of Energy's Oak Ridge and Argonne national laboratories has performed the first room-temperature X-ray measurements on the SARS-CoV-2 main protease -- the enzyme that enables the virus to reproduce.

26 Jun 2020

Entos Pharmaceuticals selects two lead DNA vaccine candidates for COVID-19

Entos Pharmaceuticals, a healthcare biotechnology company developing nucleic acid medicines with its Fusogenix drug delivery platform, today announced the selection of two lead candidates for a pan-coronavirus Fusogenix DNA vaccine from its prototyping program launched at the onset of the global COVID-19 pandemic.

25 Jun 2020

Structured 'cut-and-paste' design enables streamlined development of SARS-CoV-2 molecular probes

A seminal study by US researchers, currently available on the bioRxiv* preprint server, demonstrates how structure-based design can be efficiently employed to develop molecular probes targeting the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike and its domains, with possible future use in diagnostics, treatment and vaccine development.

24 Jun 2020

Novel vaccine platform against COVID-19 based on engineered human mesenchymal stem cells

In a recent groundbreaking bioRxiv paper, Chinese researchers describe a novel approach towards coronavirus disease (COVID-19) vaccine design based on engineered human mesenchymal stem cells, with favorable and promising antibody response.

22 Jun 2020

Novel SARS-CoV-2 antibody cocktail impeccably mimics human antibody response

By using both humanized mice and convalescent patients, the researchers from the US and Singapore successfully generated non-competing and highly potent monoclonal antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein that could potentially be combined to form antibody cocktails. Their groundbreaking paper is published in the leading research journal Science.

18 Jun 2020

BIA Separations launches novel PrimaS ligand technology to facilitate development of advanced therapies

BIA Separations, a leading bio-chromatography development and manufacturing company, today announced the introduction of its novel PrimaS ligand technology.

17 Jun 2020

Lab Automation for Biome Research

News Medical Life Sciences discussed how lab automation can improve the efficiency of biome research with Tom Copeland, Sales and Marketing Coordinator of Hudson Robotics, at Pittcon 2020.

From Hudson Robotics 11 May 2020

Interleukin-12 electroporation led to clinical responses in patients with advanced melanoma

Combining intratumoral electroporation of interleukin-12 (IL-12) DNA (tavokinogene telseplasmid, or TAVO) with the immune checkpoint inhibitor pembrolizumab (Keytruda) led to clinical responses in patients with immunologically quiescent advanced melanoma, according to results from a phase II trial.

6 May 2020

Epivax and Entos Pharmaceuticals to develop DNA-based vaccine for COVID-19

Entos Pharmaceuticals (Entos), a healthcare biotechnology company that develops next generation nucleic acid medicines using the Fusogenix drug delivery platform, today announced a collaboration with EpiVax, Inc. (EpiVax), a world leading informatics and immunology biotechnology company with a proven track record in vaccine development.

28 Apr 2020

A new tool for developing gene therapies against cancer, genetic disorders, and blood diseases

A UCLA-led research team today reports that it has developed a new method for delivering DNA into stem cells and immune cells safely, rapidly and economically.

28 Apr 2020

Antibiotic exposure and its priming effect on disease-causing bacteria

Antibiotics save lives -- but using them also helps antibiotic-resistant strains evolve and spread. Each year, antibiotic-resistant bacteria infect some 2.8 million people in the United States, killing more than 35,000, according to the Centers for Disease Control and Prevention.

27 Apr 2020

FUJIFILM Diosynth Biotechnologies Enters Strategic Partnership With OXGENE™ To Address Supply Bottlenecks In Gene Therapy Development And Manufacturing

FDB announced a strategic partnership with OXGENE™, an industry leader in the design and development of gene therapy technologies.

From OXGENE 23 Apr 2020